Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

BMC Cancer

Yan Tong¹  Olumide B. Gbolahan²  Safi Shahda³  Amikar Sehdev⁴  Bert O’Neil⁵ 

[1] 0000 0001 2287 3919, grid.257413.6, Department of Biostatistics-HS3000, Indiana University School of Medicine, 410 West 10th; Street, 46202, Indianapolis, IN, USA;0000 0001 2287 3919, grid.257413.6, Department of Hematology Oncology, Indiana University School of Medicine, 535 Barnhill Drive, RT 473, 46202, Indianapolis, IN, USA;0000 0001 2287 3919, grid.257413.6, Department of Hematology Oncology, Indiana University School of Medicine, Indiana Cancer Pavilion, Suite 130-C 535; 535 Barnhill Drive, 46202-5289, Indianapolis, IN, USA;0000 0001 2287 3919, grid.257413.6, Department of Hematology Oncology, Indiana University School of Medicine, Indiana Cancer; Pavilion, 535 Barnhill Drive, 46202-5289, Indianapolis, IN, USA;0000 0001 2287 3919, grid.257413.6, Indiana University School of Medicine, Indiana Cancer Pavilion; 535 Barnhill Drive, 46202-5289, Indianapolis, IN, USA;

关键词: Recurrent pancreatic ductal adenocarcinoma;    Recurrent pancreatic cancer;    Metastatic pancreatic cancer;    FOLFIRINOX;    Gemcitabine-nab paclitaxel;    Combination chemotherapy;   

DOI  :  10.1186/s12885-019-5630-4

来源: publisher

【 摘 要 】

BackgroundOnly a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC. As such, there is a paucity of data to guide treatment after relapse, and patients are treated similarly to those with de novo metastatic PDAC (mPDAC). We evaluated the patterns of chemotherapy use and over-all survival (OS) in patients with recurrent PDAC (rPDAC) following curative therapy.MethodsIn this retrospective study, the Indiana University pancreatic cancer database was used to identify patients with PDAC who underwent curative resection and subsequently developed recurrence. Demographics, tumor and treatment characteristics were collected. Patients were broadly divided into those who received chemotherapy for rPDAC and those who did not. Patients in the former category were further subdivided into those who received single agent therapy, any standard combination therapy (5-fluorouracil/irinotecan/oxaliplatin combination or gemcitabine/nab-paclitaxel) and those who received non-standard combinations. Survival analysis was performed by the Kaplan-Meier method. Log rank tests were used to determine differences in survival between treated rPDAC patients and those not treated. Cox regression analysis was employed to evaluate factors associated with OS.ResultsWe identified 435 patients with resected PDAC treated between 2008 and 2014. Two hundred and twenty-three patients (51.2%) were diagnosed with rPDAC. Of these, 140 patients (63%) received chemotherapy whereas 71 patients (32%) did not receive chemotherapy. The 74 patients (53%) who received any standard, approved multiagent combination regimen had a median OS of 14 months compared to 8 months for the 47 patents (34%) who received other non-standard combinations and the 19 (13%) who received single agent therapy (P = 0.029). Multivariate cox regression analysis showed that margin negative resection, peri-operative therapy, radiotherapy and the use of any chemotherapy for rPDAC were associated with improved OS.ConclusionOur findings support the use of standard approved multi-agent therapy in rPDAC. Patients derive significant benefit from these standard combination therapies with median OS that is comparable to what is observed with treatment for de novo mPDAC.

【 授权许可】

CC BY